CELUW - Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress | Benzinga
FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company's Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
Dr. Hariri's keynote, titled, "Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders," will address cellular immunotherapy's broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson's disease. Dr. Hariri will also participate on two other keynote panels at the Congress: the first on March 14, titled, "Future of Neurotech from Cell Therapy and Medical Devices to Policy," and the second on March 16, titled, "Cancer Neurodegenerative Disorders and Cell Therapy."
"In a rapidly evolving cellular medicine industry, Celularity's mission is to develop transformative therapies for patients suffering from neurological disorders using our proprietary technology platform, which employs placental-derived cells, biological materials and by-products," said Dr. Hariri. "Celularity and our predecessor parent company, Celgene, have done extensive work in neuroinflammatory diseases, including multiple sclerosis, and studied the promise of cellular and regenerative therapy in treating age-related cognitive decline. As the SBMT and World Brain Mapping Foundation (WBMF) are helping to drive collaboration between the academic and industrial communities, as well as offering potential commercial and investment opportunities, the Annual World Congress is the perfect forum to discuss our research."
"The future of ...